SCHEMBL3978178

SCHEMBL3978178

C#CCNC(=O)c1cc(C(=O)c2c(-c3ccc(Br)cc3)noc2C)c[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
ALDH1A1 P00352 5/20 0.53
LMNA P02545 2/20 0.53
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HKDC1 Q2TB90 1/20 0.42
MCOLN3 Q8TDD5 1/20 0.42
CYP1A2 P05177 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
MAPK7 Q13164 2/20 0.38
MAPK14 Q16539 2/20 0.38
FNTA P49354 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3980049 0.90 HTT (0.58) HTTSMN1; SMN2ALDH1A1LMNAKMT2A
SCHEMBL3977034 0.90 HTT (0.58) HTTSMN1; SMN2ALDH1A1LMNAKMT2A
SCHEMBL3980271 0.90 HTT (0.70) HTTSMN1; SMN2ALDH1A1LMNAKMT2A
SCHEMBL3977973 0.89 HTT (0.61) HTTSMN1; SMN2ALDH1A1LMNAKMT2A
SCHEMBL3977283 0.89 HTT (0.54) HTTSMN1; SMN2ALDH1A1LMNAKMT2A
SCHEMBL3979182 0.89 HTT (0.56) HTTSMN1; SMN2ALDH1A1LMNAKMT2A
SCHEMBL13842409 0.87 SMN1; SMN2 (0.59) HTTSMN1; SMN2ALDH1A1LMNAKMT2A
SCHEMBL3976561 0.87 SMN1; SMN2 (0.59) HTTSMN1; SMN2ALDH1A1LMNAKMT2A
SCHEMBL13842429 0.86 HTT (0.58) HTTSMN1; SMN2ALDH1A1LMNAKMT2A
SCHEMBL13842443 0.86 HTT (0.58) HTTSMN1; SMN2ALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538132-B2 Isoxazolo derivatives HOFFMAN-LA ROCHE INC. (US) 2009-05-26 US disclosed
US-7538132-B2 Isoxazolo derivatives HOFFMAN-LA ROCHE INC. (US) 2009-05-26 US disclosed
US-7538132-B2 Isoxazolo derivatives HOFFMAN-LA ROCHE INC. (US) 2009-05-26 US disclosed
EP-1931661-B1 ISOXAZOLO DERIVATIVES AS GABA A ALPHA5 INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-11-19 EP disclosed
US-20070066668-A1 Isoxazolo derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-03-22 US disclosed
US-20070066668-A1 Isoxazolo derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-03-22 US disclosed
US-20070066668-A1 Isoxazolo derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066668-A1 Isoxazolo derivatives GABRA5, GABRA4, GABRA1 HTT 2677/4885SMN1; SMN2 3215/4885ALDH1A1 435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.